click enter text
prettier bridg
earlier today publish note includ
estim compani exposur china correct
estim mid-singl digit note given feedback
apolog confus
investor focu coronaviru tougher comp
bridg say valid point consensu achiev
scrub mechan revenu bridg
beyond evalu mechan account past inventori
challeng input consid size primescan primemil
suresmil opportun detail bridg exhibit
take account inventori dynam ex npi underli sale
growth track posit though modestli next year
ramp primemil allow continu grow organ
ex-pm/fx even assum underli improv tie
one ds new manag effort drive commerci execut
launch ancillari product all-in larg remain posit drive
result maintain peer perform rate lower pt
margin earn estim come reinvest cost save
trade fundament data
upsid target
primemil primescan upgrad cycl recent introduc
primemil add upgrad cycl primescan support revenu
growth ahead industri growth rate note
announc primemil believ primemil could add much
annual sale base instal base estim
upgrad price conserv model sale ramp
coronaviru risk number coronaviru remain risk difficult
size compani far earn cycl provid estim
impact sale dental compani gener much lower exposur
china sar outbreak asia total sale
time hsd asia sale slow doubl digit averag
recov estim china msd sale
grow hsd present risk near-term china slow even declin
model chang valuat updat increas revenu
estim reflect low growth organ forecast total top
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
line growth driven npi margin bridg driven compani cost save effort ep
estimate ahead street result point soft end market insight driver
limit result larg reflect product ration salesforc reorgan
page
exhibit guidanc tracker outlook
exhibit total compani organ revenu growth adjust
near-term
page
organ growth ex
revenu bridg refin revenu bridg
assess organ growth rate
compani adjust impact chang
inventori dealer new
improv cours level
growth ex new product improv
stack growth remain flat
stack growth new product benefit
meaning primescan suppli catch
demand primescan releas new
sale introduct primemil drive new
upgrad cycl mill machin addit
exclud new product introduct organ
growth estim adjust reflect impact
inventori stocking/destock dealer
venlo plant disrupt time ds world
manag greater ny dental
meet point attend year ds
world vs previou meet indic
demand one ds promot program
help captur market share consum
greater cross-sel though still
unproven organ revenu growth also
improv lap tough compar
see product
wolf vs street estim
ahead street revenu given dynam
primescan primemil well stabil
dental consum ds one program
exhibit revenu estim also
ahead street estim despit
expect organ growth moder
tougher compar continu
benefit new product introduct
ep estim ahead street
expect margin improv continu
least xray cost reduct
effort compar recent result
view
predict sinc along
reorg product ration effort new
product introduct note
estimate revenu consum growth steadi return growth thereaft new product introduct invest global scale faster grow region overal growth dental marketnet debt ebitdainvest grade util balanc sheet enhanc ep growthebit end end restructur save portfolio shape continu plan margin expans growthdoubl digit acceler ep growth near-term cost save revenu growth adj inventoryy/i organ growth stack growth ratey/i organ growth ex npisforecast
exhibit price-to-earnings rel averag
recent separ trend dental rel
near-term risk estim relat
coronaviru impact china believ
factor dental stock declin
compar market
pullback note last major viru cycl
predict dental compani
much smaller exposur china time
sar stage viru still emerg
soon know extens impact
note compani msd
sale china impact region
primemil underestim primescan
upgrad cycl gotten fair amount attent
believ primemil offer could
meaning driver revenu growth next
year detail
note
announc primemil point
potenti disrupt first year sale older
model disrupt manufactur
sale new mill machin take time
contribut consist sirona
experienc launch
mc xl machin last cycl cad/cam
revenu start acceler two quarter
launch mc xl near-term could also see
margin
impact manufactur cost
increas sale start ramp
detail primemil estim exhibit
margin valuat margin bridg exhibit
separ contribut cost
save effort organ trend show
forecast go forward organ
trend margin conserv small
declin organ margin ex impact
cost save effort beyond estim
cost reduct program contribut
also conserv
compar manag target
cost reduct
compani
reiter recent meet lower pt
year-end pt conserv
margin forecast higher fcfi use
yield appli estim
essenti in-lin devic
median exclud exhibit factor
risk relat coronaviru
page
price-to-earnings premium ical etf p/edent price-to-earnings premium devic ebitda compound-annual-growth-rate ev-ebitda vs estimate ebitda compound-annual-growth-rate tool op margin y/i changeorgan op margin stack changenomin op margin y/i changeforecast
exhibit estim benefit primescan sale
exhibit estim benefit primemil sale
primescan growth recent survey work
slightli less posit primescan still
believ primescan sale could reach scale
algn itero given strong earli launch
primescan estim could reach half
sale itero increment
primescan continu contribut
growth compani expand product
match demand intern avail
increas addit forecast benefit
approxim suresmil
new endodont product
primemil contribut disclos instal
base mill machin estim
upgrad price primemil indic total
replac market opportun billion
estim replac cycl could take place
year similar year sinc last major
mill machin introduct
taken conserv estim year
replac cycl calcul contribut
page
estimate mn except ep estimate ep bpstax bp net estim sale itero scanner captur growth estim sale impact mm lowhighinstal millsprimemil estimate price total replac opportun mn replac cycl potenti annual revenue
inventori
exhibit us organ growth expect volatil
exhibit european growth face easier comp
exhibit rest world growth expect continu
exhibit organ revenu bridg adjust inventori chang
page
revenu growth adj inventoryy/i organ growth stack growth ratey/i organ growth ex us organ growth rate ex inventoryorgan y/i growth stack europ organ growth rate ex inventoryorgan y/i growth stack row organ growth rate ex inventoryorgan y/i growth stack adj intern us- us- inventory/tim items- new product introduct primescan suresmil estimate organ revenu y/i estimate organ stack
exhibit organ revenu trend region product line
exhibit quarterli sequenti trend technolog
exhibit quarterli sequenti trend consum
note adjust inventori chang distributor partner
page
estimate ex intern organ ex inventory/tim organ ex ex inventori year intern organ ex inventory/tim organ ex new product dental revenu dental consum revenu ebit impact spend program
page
yieldfcf compound-annual-growth-rate ebitda compound-annual-growth-rate ev-ebitda vs estimate ebitda compound-annual-growth-rate tool ntm price-to-earnings ratio median price-to-earnings premium compound-annual-growth-rate
exhibit fcfi modestli higher averag
fcfi pt in-lin averag
page
note figur million unless state per-shar term
page
metal margin inc pre-tax tax unconsolid net non incom net cont dilut non margin
note figur million unless state per-shar term
page
